VOGX (Vogenx) Total Liabilities: $1.60 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

VOGX Vogenx Inc VOGX
8 GF Score
Price $14.09
View Full Analysis

What is Vogenx Total Liabilities?

Vogenx VOGX +8.38% 8 Total Liabilities is $1.60 Mil as of Dec. 2025. GuruFocus rates VOGX with a GF Score™ of 8/100.

Vogenx's Total Liabilities for the quarter that ended in Dec. 2025 was $1.60 Mil.

Vogenx's quarterly Total Liabilities increased from . 20 ($0.00 Mil) to Dec. 2024 ($0.46 Mil) and increased from Dec. 2024 ($0.46 Mil) to Dec. 2025 ($1.60 Mil).

Vogenx's annual Total Liabilities increased from . 20 ($0.00 Mil) to Dec. 2024 ($0.46 Mil) and increased from Dec. 2024 ($0.46 Mil) to Dec. 2025 ($1.60 Mil).

Vogenx Total Liabilities Historical Data

* Premium members only.

The historical data trend for Vogenx's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vogenx Total Liabilities Chart

Vogenx Annual Data
Trend Dec24 Dec25
Total Liabilities
0.46 1.60

Vogenx Semi-Annual Data
Dec24 Dec25
Total Liabilities 0.46 1.60
VOGX
8GF Score
Vogenx Inc VOGX
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vogenx Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Vogenx's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=1.589+(0+0.011
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=1.60

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=0.681--0.919
=1.60

Vogenx's Total Liabilities for the quarter that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=1.589+(0+0.011
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=1.60

Total Liabilities=Total Assets (Q: Dec. 2025 )-Total Equity (Q: Dec. 2025 )
=0.681--0.919
=1.60

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $1.60 Mil mean?
Vogenx (VOGX) has a Total Liabilities of $1.60 Mil as of Dec. 2025. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Vogenx and its competitors.
Is Vogenx's Total Liabilities too high?
Vogenx's current Total Liabilities is $1.60 Mil. Overall, Vogenx has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Vogenx's Total Liabilities compare to ?
Vogenx's Total Liabilities of $1.60 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Vogenx and its competitors. Vogenx's current Total Liabilities is $1.60 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vogenx stock overvalued right now?
Vogenx (VOGX) has a current Total Liabilities of $1.60 Mil. The current Total Liabilities is $1.60 Mil. Vogenx's overall GF Score™ is 8/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Vogenx (VOGX), the current Total Liabilities is $1.60 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Vogenx Business Description

Comparable Companies
Address 3901 Barrett Drive, P.O. Box 19469, Suite 300, Raleigh, NC, USA, 27609
Vogenx Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for the treatment of serious diseases associated with dysfunctions in human metabolism, including post-bariatric hypoglycemia, or PBH, and gastroparesis. The company's flagship product candidate, mizagliflozin, is an orally administered, minimally absorbed, small molecule drug candidate being developed for the treatment of post-bariatric hypoglycemia (PBH), gastroparesis and GIP-induced Cushing's Syndrome. It operates as a single reportable segment engaged in the discovery and development of treatments for serious metabolic and gastrointestinal diseases.
8GF Score

Get the complete analysis for VOGX

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$14.09
Price